IRF3 and osteosarcoma: Having established that the SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway in osteosarcoma cells, we investigated the potential synergistic effects of the STING pathway agonist 2’3’-cGAMP and the SGLT2 inhibitor in osteosarcoma.